Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030


Head And Neck Cancer Therapeutics Market Growth & Trends

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights
  • Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
  • Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
  • Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
  • The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy Type
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Therapy Type and Route of Administration Segment Snapshot
2.3 Distribution Channel Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope
3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increase in Prevalence of Head and Neck Cancers
3.2.1.2 Rising Geriatric Population
3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
3.2.2 Market Restraint Analysis
3.2.2.1 Paucity of Data Related to Safety and Efficacy
3.2.2.2 High Cost of Treatment
3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Macroeconomic Analysis
3.4 Pipeline Analysis
3.4.1 Phase 3 Pipeline drugs under clinical trails
Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
4.3 Chemotherapy
4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.4 Immunotherapy
4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.5 Targeted Therapy
4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
5.3 Injectable
5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
5.4 Oral
5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
6.3 Retail & Specialty Pharmacies
6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.4 Hospital Pharmacies
6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.5 Online Pharmacies
6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel
7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
7.2 North America
7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2.3 Target Disease: Cancer Incidence
7.2.2.4 Market and Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3.3 Target Disease: Cancer Incidence
7.2.3.4 Market and Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 Key Country Dynamics
7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2.3 Target Disease Prevalence
7.3.2.4 Market and Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3.3 Target Disease Prevalence
7.3.3.4 Market and Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4.3 Target Disease Prevalence
7.3.4.4 Market and Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Spain
7.3.5.1 Key Country Dynamics
7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5.3 Target Disease Prevalence
7.3.5.4 Market and Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Key Country Dynamics
7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6.3 Target Disease Prevalence
7.3.6.4 Market and Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7.3 Target Disease Prevalence
7.3.7.4 Market and Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8.3 Target Disease Prevalence
7.3.8.4 Market and Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9.3 Target Disease Prevalence
7.3.9.4 Market and Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.2.3 Target Disease Prevalence
7.4.2.4 Market and Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.3.3 Target Disease Prevalence
7.4.3.4 Market and Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4.3 Target Disease Prevalence
7.4.4.4 Market and Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.5.3 Target Disease Prevalence
7.4.5.4 Market and Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Key Country Dynamics
7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.6.3 Target Disease Prevalence
7.4.6.4 Market and Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 South Korea
7.4.7.1 Key Country Dynamics
7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.7.3 Target Disease Prevalence
7.4.7.4 Market and Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3.3 Target Disease: Cancer Incidence
7.5.3.4 Market and Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6 Middle East and Africa
7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 Key Country Dynamics
7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Key Country Dynamics
7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, By Key Market Participants
8.2 Company Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Eli Lilly and Company
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Sanofi
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.6. Merck & Co., Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.7. Cumberland Pharmaceuticals, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.8. Bristol-Myers Squibb Company (BMS)
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.9. AstraZeneca
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.10. Takeda Pharmaceutical Company Limited
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.11. Teva Pharmaceutical Industries Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings